文献速递主动脉疾病

门诊EVAR的适用率评估

Eligibility Rates for Ambulatory EVAR.
PubMed 文献 · Ann Vasc Surg · 2019-02-06

本研究回顾性分析245例腹主动脉瘤手术患者,排除解剖不适合EVAR、急诊手术及ASA 4级者后,对117例重新评估门诊EVAR(EVAR-Ambu)的适用率及医疗经济影响。按HAS或SVS标准评估手术风险时,经皮途径的适用率分别为37%和49%;若传统手术入路也可接受,则分别增加10%和11%。门诊EVAR在经济上对医疗系统有利,但个体层面收益较低,其安全性需前瞻性研究确认。

要点

  • 在筛选后的117例腹主动脉瘤患者中,经皮途径门诊EVAR的适用率按HAS标准为37%,按SVS标准为49%。
  • 若传统手术入路也可接受,门诊EVAR适用率可分别增加10%(HAS)和11%(SVS)。
  • 术后1晚常规住院每日费用603€,日间手术单元为490€,但机构收入相同,门诊EVAR每例结余+122€。

核心结论

  • 门诊EVAR在相当比例的肾下腹主动脉瘤患者中是可行的,其医疗经济价值对医疗系统确实存在,但在个体层面显得较低。
  • 该 approach 在临床实践中的安全性必须通过针对选定患者的前瞻性研究来确认。

研究设计与样本

  • 回顾性研究,2014年1月至2016年12月期间共245例腹主动脉瘤手术患者,排除解剖不适合EVAR、急诊手术及ASA 4级者后,对剩余117例病历进行回顾性评估门诊EVAR的适用性。
  • 适用标准包括:正常手术风险、门诊手术的后勤可行性(住所距医院<1小时、有亲属可用)、以及根据CT血管造影评估的经皮途径解剖可行性。
  • 手术风险分别根据法国高级卫生管理局(HAS)和血管外科学会(SVS)评分评估。

主要发现

  • 117例患者中,按HAS或SVS标准评估手术风险时,经皮途径的门诊EVAR适用率分别为43例(37%)和57例(49%)。
  • 若传统手术入路也被认为与门诊EVAR兼容,则按HAS或SVS标准分别额外增加12例(10%)和13例(11%)适用患者。
  • 医疗经济评估显示,初始干预成本主要取决于支架移植物和手术室服务成本;EVAR后1晚常规住院每日费用为603€,日间手术单元为490€。
  • 日间手术单元与1晚常规住院的机构收入相同;据估计,门诊EVAR每例患者收支结余为+122€,而住院1晚或2晚分别为+10€或+119€。

关键数值与推荐

  • 门诊EVAR适用标准:正常手术风险、门诊手术的后勤可行性(住所距医院<1小时、有亲属可用)、根据CT血管造影评估的经皮途径解剖可行性。
  • 手术风险评估采用法国HAS和SVS评分。
  • 经皮途径门诊EVAR适用率:按HAS标准为37%(43/117),按SVS标准为49%(57/117)。
  • 若传统手术入路兼容,额外适用率:按HAS标准为10%(12例),按SVS标准为11%(13例)。
  • EVAR后1晚常规住院每日费用603€,日间手术单元每日费用490€;门诊EVAR每例收支结余+122€,住院1晚为+10€,住院2晚为+119€。

临床怎么用

  • 对于解剖适合EVAR且手术风险正常、具备门诊后勤条件的肾下腹主动脉瘤患者,可考虑门诊EVAR以优化医疗资源利用。
  • 在评估门诊EVAR适用性时,需结合HAS或SVS评分以及经皮途径的解剖可行性进行个体化判断。
  • 门诊EVAR可能为医疗系统带来经济收益,但个体层面结余有限,需关注其安全性并开展前瞻性研究验证。

局限性

  • 本研究为回顾性单中心研究,样本量有限(117例),结论需前瞻性研究验证。
  • 门诊EVAR的安全性和临床实践中的可行性尚未经前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The current results of endovascular repair of abdominal aortic aneurysms (EVAR) and the wide use of percutaneous closure systems suggest that ambulatory treatment is feasible in selected patients. The objective of this study was to evaluate the rate of eligibility to ambulatory EVAR (EVAR-Ambu) and its potential medicoeconomic impact. METHODS: Between January 2014 and December 2016, 245 patients were operated of an abdominal aortic aneurysm (AAA) in our center. The 128 patients whose anatomy was unfavorable with EVAR, which were operated in urgency or who were classified as American society of anesthesiologists 4, were excluded from the study. The 117 remaining files were reexamined to evaluate the eligibility for EVAR-Ambu retrospectively. The patients were considered as eligible if they presented all the following criteria: (1) normal surgical risk, (2) logistic feasibility of an ambulatory procedure (home <1 hr away from the hospital, available relatives), and (3) anatomical criteria of percutaneous feasibility according to angio-computed tomography. The surgical risk was evaluated according to the French High Health Authority (HAS) and the Society for Vascular Surgery (SVS) score. The balance between costs and revenue was evaluated for each patient according to the length of stay. RESULTS: Among the 117 patients, 43 (37%) and 57 (49%) were eligible for EVAR-Ambu by percutaneous route according to whether the surgical risk was assessed according to the HAS or the SVS criteria. If a conventional surgical approach was considered as compatible with EVAR-Ambu, 12 (10%) and 13 (11%) additional patients were eligible according to whether the surgical risk was assessed according to the HAS or the SVS criteria, respectively. In terms of medicoeconomic evaluation, the cost of the initial intervention depended was mainly on the cost of the stent graft and the operating room services. The cost spent of 1 night conventional hospitalization (CH) after EVAR was 603€ per day versus 490€ in the Day Surgery Unit (DSU). In comparison, the revenue for the institution was identical for DSU and a 1-night CH. According to our estimates, the balance between revenue and expenditures amounted to +122€ per patient for EVAR-Ambu versus +10€ or +119€ per patient hospitalized 1 or 2 nights, respectively. CONCLUSIONS: EVAR-Ambu is possible in a substantial proportion of patients treated for infrarenal AAA. Its medicoeconomic interest is real for the health system although it appears low at the individual level. The safety of this approach in clinical practice must be confirmed by a prospective study in selected patients.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Sylvestre R, Coscas R, Javerliat I, et al. Eligibility Rates for Ambulatory EVAR. Ann Vasc Surg. 2019. PMID: 30735768. doi:10.1016/j.avsg.2018.10.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。